Melissa E. Karabinis

Melissa Karabinis has been advising clients on the full spectrum of patent issues in the life sciences for over seventeen years. Melissa has prepared and prosecuted hundreds of patent applications for clients in the following technologies: vaccines, monoclonal antibodies, biologics, gene transfer vectors, gene therapy, nucleic acid sequences, proteins, antibody-drug conjugates, cell lines, immunotherapy, generic drug products, diagnostic methods, and small molecules. Melissa has extensive experience in preparing and prosecuting patent applications in the U.S. and in foreign countries, and in managing complex patent portfolios. Melissa also has experience in rendering opinions on patent validity and patent infringement, and has been involved in interference proceedings and European oppositions.

Professional Experience
Patent Agent, Casimir Jones S.C., 2018
Senior Patent Agent, Michael Best & Friedrich LLP, 2015-2018
Technical Advisor/Patent Agent, Leydig, Voit & Mayer, Ltd., 2001-2015
Education
University of Wisconsin, M.S., Genetics, 2000
University of Kansas, B.S., Biology, 1997
Admitted
United States Patent and Trademark Office, 2002

Representative Cases
Interference No. 104,756 (represented GenVec against Sumitomo Pharmaceuticals in patent interference pertaining to adenoviral vectors, complementary cell lines, and related technology)
Interference No. 104,822 (represented GenVec against Transgene in patent interference pertaining to adenoviral vectors, complementary cell lines, and related technology)
Interference No. 104,825 (represented GenVec against Cell Genesys in patent interference pertaining to adenoviral vectors, complementary cell lines, and related technology)
Interference No. 104,827 (represented GenVec against the University of Texas in patent interference pertaining to adenoviral vectors, complementary cell lines, and related technology)
Interference No. 104,829 (represented GenVec against Gencell in patent interference pertaining to adenoviral vectors, complementary cell lines, and related technology)
Publications
1.  “Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice,” Kolom (Karabinis) et al., Carcinogenesis, 22(2): 343-6 (2001).